Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPT-IN: Optimizing HIV PEP Delivery
NCT03259698Phase 2Unknown
- Sponsor
- Unity Health Toronto
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (4 arms), sponsored by Unity Health Toronto. Primary endpoint: Self-reported completion of a full course of PEP medications and receipt of a final HIV test result at 12 weeks. Status: unknown.
Beyond the preview
Go deeper on NCT03259698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03259698.